Invention Grant
- Patent Title: Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
-
Application No.: US16646690Application Date: 2018-09-12
-
Publication No.: US11421034B2Publication Date: 2022-08-23
- Inventor: Katherine E. Lewis , Serena Kimi Perna , Michael Carleton , Ke Xu , Penny Phillips , Dimple Pandya , Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Janine Powers , Ernestine Lee
- Applicant: Five Prime Therapeutics, Inc. , Bristol-Myers Squibb Company
- Applicant Address: US CA South San Francisco; US NJ Princeton
- Assignee: Five Prime Therapeutics, Inc.,Bristol-Myers Squibb Company
- Current Assignee: Five Prime Therapeutics, Inc.,Bristol-Myers Squibb Company
- Current Assignee Address: US CA South San Francisco; US NJ Princeton
- Agency: McNeill Baur PLLC
- International Application: PCT/US2018/050711 WO 20180912
- International Announcement: WO2019/055537 WO 20190321
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K47/69 ; A61K47/64 ; A61P35/00 ; A61K31/337 ; A61K31/513 ; A61K31/7068 ; A61K39/395 ; C12Q1/6886 ; A61K39/00
Abstract:
The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
Public/Granted literature
- US20210009697A1 Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic Cancer Public/Granted day:2021-01-14
Information query
